Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injections, Intravenous Clear all
Terminated Phase 1 Interventional

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

NCT00527410
View directory record Official record
Conditions
Leptomeningeal Carcinomatosis
Interventions
RTA 744
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

NCT00606489
View directory record Official record
Conditions
Burns
Interventions
Caldolor, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Orlando, Florida • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

NCT02234297
View directory record Official record
Conditions
Glioma
Interventions
BLZ-100
Drug
Lead sponsor
Blaze Bioscience Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

NCT02337062
View directory record Official record
Conditions
PONV
Interventions
APD421, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
14
States / cities
Sheffield, Alabama • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 22, 2026, 11:38 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

NCT07687784
View directory record Official record
Conditions
Iron Deficiency Anemia (IDA)
Interventions
Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®]
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Coral Gables, Florida • Melbourne, Florida • The Villages, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

NCT01131000
View directory record Official record
Conditions
Fever
Interventions
Ibuprofen, Normal Saline
Drug · Other
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

NCT01002573
View directory record Official record
Conditions
Fever
Interventions
ibuprofen, acetaminophen
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Up to 16 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
17
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Intravenous (IV) Catheterization in Children

NCT00444756
View directory record Official record
Conditions
Pain
Interventions
J-tip jet injection of 1% buffered lidocaine
Procedure
Lead sponsor
Norton Healthcare
Other
Eligibility
8 Years to 15 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 8, 2007 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

NCT04189588
View directory record Official record
Conditions
Oncology Patients Receiving Chemotherapy
Interventions
Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

NCT04307186
View directory record Official record
Conditions
Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Study of APD421 as PONV Treatment (Prior Prophylaxis)

NCT02646566
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
APD421, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Miami, Florida • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 22, 2026, 11:38 PM EDT
Not listed Phase 3 Interventional

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

NCT00017784
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Beverly Hills, California • Paramount, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:38 PM EDT
Recruiting Phase 3 Interventional

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

NCT07388498
View directory record Official record
Conditions
Uncontrolled Gout
Interventions
Pegloticase, Methotrexate
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Anchorage, Alaska • Searcy, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

NCT01280240
View directory record Official record
Conditions
Patients With Chemotherapy Induced Anemia (CIA)
Interventions
Monofer(R)
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Baltimore, MD, Maryland • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

NCT07413133
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070
View directory record Official record
Conditions
Pharmacokinetics of ASP2408, Healthy Subjects
Interventions
ASP2408, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 22, 2026, 11:38 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery

NCT02266797
View directory record Official record
Conditions
Dysphagia After Anterior Cervical Decompression and Fusion of the Spine
Interventions
Dexamethasone, Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Westbury, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

NCT04770935
View directory record Official record
Conditions
Von Willebrand's Disease (VWD)
Interventions
efanesoctocog alfa (BIVV001)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

NCT00001017
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 22, 2026, 11:38 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vancomycin in TKAs

NCT07282782
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Vancomycin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

US Phase III Study of APD421 in PONV

NCT01991860
View directory record Official record
Conditions
PONV
Interventions
APD421- Amisulpride for IV injection, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 2Phase 3 Interventional

Study to Reduce Intravenous Exposures (STRIVE)

NCT00391482
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peer Mentoring Intervention for HCV-Infected IDUs
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 35 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

NCT01957735
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumor
Interventions
BP31510 monotherapy, BP31510 in combination with chemotherapy
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Sunnyvale, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 22, 2026, 11:38 PM EDT